| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Hoerter Steven L., Director
Sold 4,893 shares ($268K) |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | S-8 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway |
| 05 Nov 2026 |
Form 4: Azoulay Salomon, Chief Medical Officer
Sold 373 shares ($20.1K) |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 144 |
| 22 Oct 2026 |
Form 4: Radovich Peter, Director
Granted 18,200 Stock option (right to buy) |
| 22 Oct 2026 |
Form 3: Radovich Peter, Director
No securities owned |
| 22 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed P... |
| 27 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | SCHEDULE 13D/A |
| 10 Aug 2026 | SCHEDULE 13D/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting |
| 05 Aug 2026 |
Form 4: Azoulay Salomon, Chief Medical Officer
Sold 370 shares ($24.3K) |
| 04 Aug 2026 | 144 |
Loading...